Vertex Pharmaceuticals: Drugs That Are Making It Happen
Vertex Pharmaceuticals’ (VRTX) Kalydeco generated sales of $249.5 million in the first quarter, up from $185.7 million YoY (year-over-year). The drug is targeted to treat cystic fibrosis patients with G551D mutation in the CFTR gene. The increase was due to additional patients being treated with Kalydeco after Vertex completed reimbursement discussions in non-US jurisdictions and due to an increase in the number of eligible patients to receive Kalydeco through label expansion.